Report cover image

Global Peptide Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 195 Pages
SKU # APRC20106383

Description

Summary

According to APO Research, The global Peptide Antibiotics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Peptide Antibiotics include AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Pacgen Life Science Corporation, Phosphagenics, Savara Pharmaceuticals, Theravance and Vicuron Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide Antibiotics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide Antibiotics, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Antibiotics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Antibiotics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Antibiotics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide Antibiotics sales, projected growth trends, production technology, application and end-user industry.


Peptide Antibiotics Segment by Company

AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Pacgen Life Science Corporation
Phosphagenics
Savara Pharmaceuticals
Theravance
Vicuron Pharmaceuticals
GlaxoSmithKline
Pfizer
Eli Lilly
Novartis

Peptide Antibiotics Segment by Type

Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics

Peptide Antibiotics Segment by Application

Pharma & Healthcare
Food Industry
Commodities
Other

Peptide Antibiotics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Antibiotics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Peptide Antibiotics Market Size, 2020 VS 2024 VS 2031
1.3 Global Peptide Antibiotics Market Size Estimates and Forecasts (2020-2031)
1.4 Global Peptide Antibiotics Sales Estimates and Forecasts (2020-2031)
1.5 Global Peptide Antibiotics Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Peptide Antibiotics Market Dynamics
2.1 Peptide Antibiotics Industry Trends
2.2 Peptide Antibiotics Industry Drivers
2.3 Peptide Antibiotics Industry Opportunities and Challenges
2.4 Peptide Antibiotics Industry Restraints
3 Peptide Antibiotics Market by Manufacturers
3.1 Global Peptide Antibiotics Revenue by Manufacturers (2020-2025)
3.2 Global Peptide Antibiotics Sales by Manufacturers (2020-2025)
3.3 Global Peptide Antibiotics Average Sales Price by Manufacturers (2020-2025)
3.4 Global Peptide Antibiotics Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Peptide Antibiotics Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Peptide Antibiotics Manufacturers, Product Type & Application
3.7 Global Peptide Antibiotics Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Peptide Antibiotics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Antibiotics Players Market Share by Revenue in 2024
3.8.3 2024 Peptide Antibiotics Tier 1, Tier 2, and Tier 3
4 Peptide Antibiotics Market by Type
4.1 Peptide Antibiotics Type Introduction
4.1.1 Ribosomal Synthesized Peptide Antibiotics
4.1.2 Non-Ribosomally Synthesized Peptide Antibiotics
4.2 Global Peptide Antibiotics Sales by Type
4.2.1 Global Peptide Antibiotics Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Peptide Antibiotics Sales by Type (2020-2031)
4.2.3 Global Peptide Antibiotics Sales Market Share by Type (2020-2031)
4.3 Global Peptide Antibiotics Revenue by Type
4.3.1 Global Peptide Antibiotics Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Peptide Antibiotics Revenue by Type (2020-2031)
4.3.3 Global Peptide Antibiotics Revenue Market Share by Type (2020-2031)
5 Peptide Antibiotics Market by Application
5.1 Peptide Antibiotics Application Introduction
5.1.1 Pharma & Healthcare
5.1.2 Food Industry
5.1.3 Commodities
5.1.4 Other
5.2 Global Peptide Antibiotics Sales by Application
5.2.1 Global Peptide Antibiotics Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Peptide Antibiotics Sales by Application (2020-2031)
5.2.3 Global Peptide Antibiotics Sales Market Share by Application (2020-2031)
5.3 Global Peptide Antibiotics Revenue by Application
5.3.1 Global Peptide Antibiotics Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Peptide Antibiotics Revenue by Application (2020-2031)
5.3.3 Global Peptide Antibiotics Revenue Market Share by Application (2020-2031)
6 Global Peptide Antibiotics Sales by Region
6.1 Global Peptide Antibiotics Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Peptide Antibiotics Sales by Region (2020-2031)
6.2.1 Global Peptide Antibiotics Sales by Region (2020-2025)
6.2.2 Global Peptide Antibiotics Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Peptide Antibiotics Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Peptide Antibiotics Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Peptide Antibiotics Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Peptide Antibiotics Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Peptide Antibiotics Revenue by Region
7.1 Global Peptide Antibiotics Revenue by Region
7.1.1 Global Peptide Antibiotics Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Peptide Antibiotics Revenue by Region (2020-2025)
7.1.3 Global Peptide Antibiotics Revenue by Region (2026-2031)
7.1.4 Global Peptide Antibiotics Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Peptide Antibiotics Revenue (2020-2031)
7.2.2 North America Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Peptide Antibiotics Revenue (2020-2031)
7.3.2 Europe Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Peptide Antibiotics Revenue (2020-2031)
7.4.2 Asia-Pacific Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Peptide Antibiotics Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 AMP Therapeutics
8.1.1 AMP Therapeutics Comapny Information
8.1.2 AMP Therapeutics Business Overview
8.1.3 AMP Therapeutics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 AMP Therapeutics Peptide Antibiotics Product Portfolio
8.1.5 AMP Therapeutics Recent Developments
8.2 Hospira
8.2.1 Hospira Comapny Information
8.2.2 Hospira Business Overview
8.2.3 Hospira Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Hospira Peptide Antibiotics Product Portfolio
8.2.5 Hospira Recent Developments
8.3 Kasten
8.3.1 Kasten Comapny Information
8.3.2 Kasten Business Overview
8.3.3 Kasten Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Kasten Peptide Antibiotics Product Portfolio
8.3.5 Kasten Recent Developments
8.4 Madam Therapeutics
8.4.1 Madam Therapeutics Comapny Information
8.4.2 Madam Therapeutics Business Overview
8.4.3 Madam Therapeutics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Madam Therapeutics Peptide Antibiotics Product Portfolio
8.4.5 Madam Therapeutics Recent Developments
8.5 Pacgen Life Science Corporation
8.5.1 Pacgen Life Science Corporation Comapny Information
8.5.2 Pacgen Life Science Corporation Business Overview
8.5.3 Pacgen Life Science Corporation Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio
8.5.5 Pacgen Life Science Corporation Recent Developments
8.6 Phosphagenics
8.6.1 Phosphagenics Comapny Information
8.6.2 Phosphagenics Business Overview
8.6.3 Phosphagenics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Phosphagenics Peptide Antibiotics Product Portfolio
8.6.5 Phosphagenics Recent Developments
8.7 Savara Pharmaceuticals
8.7.1 Savara Pharmaceuticals Comapny Information
8.7.2 Savara Pharmaceuticals Business Overview
8.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Savara Pharmaceuticals Peptide Antibiotics Product Portfolio
8.7.5 Savara Pharmaceuticals Recent Developments
8.8 Theravance
8.8.1 Theravance Comapny Information
8.8.2 Theravance Business Overview
8.8.3 Theravance Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Theravance Peptide Antibiotics Product Portfolio
8.8.5 Theravance Recent Developments
8.9 Vicuron Pharmaceuticals
8.9.1 Vicuron Pharmaceuticals Comapny Information
8.9.2 Vicuron Pharmaceuticals Business Overview
8.9.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio
8.9.5 Vicuron Pharmaceuticals Recent Developments
8.10 GlaxoSmithKline
8.10.1 GlaxoSmithKline Comapny Information
8.10.2 GlaxoSmithKline Business Overview
8.10.3 GlaxoSmithKline Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 GlaxoSmithKline Peptide Antibiotics Product Portfolio
8.10.5 GlaxoSmithKline Recent Developments
8.11 Pfizer
8.11.1 Pfizer Comapny Information
8.11.2 Pfizer Business Overview
8.11.3 Pfizer Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Pfizer Peptide Antibiotics Product Portfolio
8.11.5 Pfizer Recent Developments
8.12 Eli Lilly
8.12.1 Eli Lilly Comapny Information
8.12.2 Eli Lilly Business Overview
8.12.3 Eli Lilly Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Eli Lilly Peptide Antibiotics Product Portfolio
8.12.5 Eli Lilly Recent Developments
8.13 Novartis
8.13.1 Novartis Comapny Information
8.13.2 Novartis Business Overview
8.13.3 Novartis Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Novartis Peptide Antibiotics Product Portfolio
8.13.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Peptide Antibiotics Value Chain Analysis
9.1.1 Peptide Antibiotics Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Peptide Antibiotics Production Mode & Process
9.2 Peptide Antibiotics Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Peptide Antibiotics Distributors
9.2.3 Peptide Antibiotics Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.